Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cancer pharmacogenomics: achievements in basic research.

Miki Nakajima1, Tsuyoshi Yokoi

  • 1Drug Metabolism and Toxicology, Division of Pharmaceutical Sciences, Graduate School of Medical Science, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan. nmiki@kenroku.kanazawa-u.ac.jp

International Journal of Clinical Oncology
|February 25, 2005
PubMed
Summary

Genetic variations in drug-metabolizing enzymes, like cytochrome P450 (CYP), significantly impact cancer drug effectiveness and toxicity. Understanding these pharmacogenomic differences is crucial for personalized cancer chemotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CYP1A2 and ADH1C contribute to abacavir aldehyde intermediate formation in the human liver.

Drug metabolism and disposition: the biological fate of chemicals·2026
Same author

High-Speed Atomic Force Microscopy Reveals Aptamer-Mediated Conformational Trapping of METTL3-METTL14 for m<sup>6</sup>A Inhibition.

ACS applied materials & interfaces·2026
Same author

An in vitro approach to predict idiosyncratic drug-induced agranulocytosis using myeloperoxidase-derived reactive metabolites.

Drug metabolism and disposition: the biological fate of chemicals·2026
Same author

Identification of alcohol dehydrogenase (ADH) isoforms catalyzing hydroxyzine oxidation using recombinant human ADH: Serendipitous finding of potent ADH inhibition by organic solvents.

Drug metabolism and disposition: the biological fate of chemicals·2026
Same author

Arylacetamide deacetylase attenuates hepatic lipid accumulation under ER stress conditions by regulating iron-dependent oxidative stress.

Toxicology and applied pharmacology·2026
Same author

Arylacetamide deacetylase deficiency potentiates ketoconazole-induced inhibition of triazolam metabolism in mice.

Drug metabolism and pharmacokinetics·2026

Area of Science:

  • Pharmacogenomics
  • Clinical Pharmacology
  • Oncology

Background:

  • Genetic variations, specifically polymorphisms in drug-metabolizing enzymes, influence how individuals respond to medications.
  • Cytochrome P450 (CYP) enzymes play a critical role in metabolizing many therapeutic drugs, including anticancer agents.
  • Interindividual variability in drug efficacy and toxicity is a significant challenge in cancer chemotherapy due to narrow therapeutic margins.

Purpose of the Study:

  • To review the impact of genetic polymorphisms in CYP enzymes on drug pharmacokinetics.
  • To discuss the clinical relevance of CYP genetic variations in the context of cancer chemotherapy.

Main Methods:

  • Literature review focusing on pharmacogenomics and CYP enzyme polymorphisms.
  • Analysis of studies investigating the relationship between CYP genetic variations and anticancer drug response.

Related Experiment Videos

Main Results:

  • CYP polymorphisms alter the pharmacokinetics of numerous therapeutic drugs.
  • Variations in CYP enzymes affect the activation or detoxification of anticancer agents, leading to interindividual differences in efficacy and toxicity.
  • These genetic differences are clinically relevant in optimizing cancer treatment.

Conclusions:

  • Genetic polymorphisms in CYP enzymes are key determinants of patient response to cancer chemotherapy.
  • Understanding these pharmacogenomic factors is essential for improving the safety and effectiveness of anticancer drugs.
  • Pharmacogenomic approaches hold promise for tailoring cancer treatment to individual patients.